Podcasts about efs

reformation luther ande efs teologi kyrka svenska kyrkan den helige ande johannes b

Play Episode Listen Later Jun 13, 2025 60:24

I dagens avsnitt blir det Teologiskt Forum med Tomas Nygren och Johannes Börjesson från Johannelunds Teologiska Högskola kring temat Pneumatologi. Vi följer upp pingsthelgen och talar om den helige Ande. Vad finns det för missförstånd och missbruk vi behöver observera? Vad finns det för sanningar som vi behöver återerövra och återupprätta om den tredje personen i gudomen? Vi pratar karismatik, andeutgjutelse och hur man söker förnyelse och uppfyllelse av den helige Ande.

1 geste, 3 vies : Mounia Masmoudi, médecin de prélèvement

ACTUALITES - AZUR FM

Play Episode Listen Later Jun 13, 2025 0:43

La Journée mondiale du don du sang se déroulera ce samedi 14 juin. Cette année, l'Etablissement du Sang Français (EFS) fête également ses 25 ans d'engagement au servie de la santé publique. En 2023 environ 1,6 millions de dons de sang ont été réalisés en France, ce qui permet chaque année à 1 million de patients d'être soignés, tout cela grâce aux dons bénévoles de généreux citoyens.Les interviews sont également à retrouver sur les plateformes Spotify, Deezer, Apple Podcasts, Podcast Addict ou encore Amazon Music.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

spotify france radio local amazon music visitez deezer ausha vies munster podcast addict alsace geste actu la journ colmar efs mounia donneur haguenau azur fm marckolsheim

1 geste, 3 vies : Robert, donneur régulier

ACTUALITES - AZUR FM

Play Episode Listen Later Jun 13, 2025 0:15

spotify france radio local amazon music visitez deezer vie ausha vies munster podcast addict alsace geste actu la journ colmar efs donneur haguenau azur fm marckolsheim

Do the Opposite of What you Want to Do: Lionel Cable + Joi Taylor Johnson

Just Schools

Play Episode Listen Later Jun 10, 2025 32:21

In this episode of Just Schools, Dr. Jon Eckert speaks with Lionel Cable and Joi Taylor Johnson from New Hope Christian Academy in Memphis, Tennessee. New Hope, founded nearly 30 years ago is an urban, college-preparatory elementary school providing students with a challenging, intellectual, and Christ-centered education Joi, a New Hope alum and now Director of Development, shares how the school helped shape her leadership and calling. The conversation highlights New Hope's innovative scholarship model, its farm and forest learning spaces, and the school's vision for expansion. The episode ends with a powerful piece of advice from Lionel's sister, “Do the exact opposite of what you want to do and watch what God does through you.” The Just Schools Podcast is brought to you by the Baylor Center for School Leadership. Be encouraged. Connect with us: Center for School Leadership at Baylor University Jon Eckert LinkedIn Baylor MA in School Leadership Jon: Well, Lionel and Joi, it is a blessing to have you here today. I'd love for you to just give our listeners a little bit of an idea of what New Hope Christian Academy is all about, where it's at, what its history is, and what your hopes are as you move forward. Lionel: First, thanks so much, Jon, for having me and Joi this morning. So New Hope is going on 30 years old. We were founded in the basement of a church downtown Memphis in 1995, 1996. Basically, it was established because there were no high quality, just private or public education options for kids in the downtown corridor. So we were founded to just offer teaching, learning, discipleship to families in need at the time. So over the past 30 years, we've grown to a little over 420 kids. 80% of our families, they have to qualify for free and reduced lunch. So the core of our mission truly is impoverished families and reaching out to them because we know in order to change that trajectory, it's two things. One, gets at the heart and that's the gospel, and then two high quality academics. If we can bridge those two things together, obviously that's going to change the trajectory of family, but then also change the trajectory of Memphis. Jon: And you have kids from age three all the way through sixth grade currently with the hope of expanding in the coming years. Is that correct? Lionel: Yeah, absolutely. Past 30 years due to our funding model, which is simply on a sliding scale, it was an impossible thing to expand. Now, with the passing of the Voucher Law in the state of Tennessee, the doors are now wide open for us to expand. So after next school year, we will be adding seventh and eighth grade. Jon: Yes. And so it's great to have your director of development on here because she has a vested interest in New Hope. So Joi, can you tell us a little bit about how you ended up back here professionally at New Hope? Joi: Yes, it's such a beautiful story honestly. I graduated from New Hope in 2007 and graduated from the sixth grade, and New Hope gave me a scholarship to go on to another independent school here in Memphis named ECS, Evangelical Christian School. And from there I went to the University of Memphis and I was all about social work and helping others. And from there, I helped start a program called the Choose 901 Alumni Program. And the alumni that we were helping were exactly the alumni from New Hope Christian Academy. And so I've kind of just always been in the works, helping our alumni get internships, jobs, and just connecting them to different opportunities and networks here in the city of Memphis. But as time went on, I kind of yearned to be back home. I wanted to be here and trying to advance the mission of New Hope. We want this school to be known all around the Memphis community and even further, because there's just so many great things happening here. This is the place that helped raise me honestly and cultivate the type of leadership and servant leadership that I have to this day. So it just made complete sense for me to come back and give my twenties, my thirties away to a school that helped make me who I am. Jon: I love that. And you mentioned this scholarship that happened after you left New Hope to go to another school. That is an unusual model. Joi: It's different. Jon: So can you talk a little bit about that Joi? How does that work? Joi: Yeah, so New Hope has always been a main proponent of school choice. Whether the actual vouchers have been passed or not, they've always just had a heart to connect students to quality education. Low-income students, underserved students to quality, Christ-centered education. And so they have always been connected to several foundations and donors who really care about what's happening in the Memphis community. And so they did the thing, they made sure it happened, and they've been doing it for 30 years now, funding scholars to go to different schools all around the city. Jon: That's such a beautiful thing, especially in a place like Memphis. Memphis is an amazing city, but it's also one of the most racially polarized cities that I've ever seen. And when they integrated Shelby County schools and they tried to connect with other counties, there was a lot of strife in that. And what I love about New Hope is it's, hey, each kid deserves an education that best fits that kid. And so ultimately you have people that have put money behind doing that, and then you have a school that's living out that mission pre-K through sixth grade, and now that's expanding with some additional opportunities. But even when it wasn't, it wasn't ever just about New Hope, but that's what I love. It was about the kids you were serving, and so therefore you're willing to use resources that a lot of schools would hold for themselves. And you're putting that scholarship with kids over the next six years to get you to the University of Memphis so that you can get through successfully. Do you know of other schools that have that model? I've been in a lot of schools and I don't know if I've ever heard that. Are you familiar with anybody else? Or Lionel, where did that idea come from? Was that just the community that you were in, or did that come from another school's model? Lionel: Yeah, so 30 years ago know when we opened, we wanted to go through 12th grade. However, the demand for high quality Christian urban education, it exploded, so we grew faster than what we intended. So the founder, Steven Carpenter, no, I can tell you the scholarship program, that was not a part of his original design for the school. It was around year four or five, we need to figure out are we going to expand or are we going to just send the kids somewhere else? And ultimately our checkbook said, okay, it's cheaper and actually easier to send the kids to our surrounding schools rather than add a grade at the time. So the model stuck. But I will tell you, Jon, you mentioned just Memphis being such a unique place. In the private sector, there are not a lot of urban ED private schools here. As a matter of fact, they're exact opposite of us. So I would like to think that our children know 30 years ago, they were really the first black and brown kids to go to some of these predominantly white spaces. So there were struggles there, but there was also opportunity for growth in terms of how New Hope could better support our kids when they left us to go to some of these other schools. So we created what was called the Alumni Support Office. There's three people in that office right now who spend 95% of their time on the campuses of the other schools to stay connected with the kids, to act as that bridge, to also act as a cheerleader, but then to also act as an advocate so that the children don't lose themselves in these spaces so that their identity can remain and then also so that they can cross the finish line. So with that particular model, we've had great success. Over the last 30 years, we have a 99.9% graduation rate from high school. 99.9% of our kids get accepted into college, 70% of which are actually working on their college degree or post-secondary. So I'd like to think it was a combination of the New Hope Scholarship opening the door, but then also that continued support that the organization offers all the way through to the finish line. Jon: Well, it's such a beautiful example of building the kingdom because it's not just a gift to your students, it's a gift to those campuses that were impoverished by the lack of diversity. They were not the kingdom because they were only serving a segment of the population. And so you enrich those campuses with the gift of your students. And so that's always one of the things when we study Brown vs Board of Education and the language of that, it's always like, well, how the black and brown kids are being harmed. And the counter argument to that is, all of the students who were not able to be exposed to different cultures and different kinds of kids and people within their own community, that's impoverishing to everyone. So you have been a gift financially in the scholarship to those schools, but to send kids out who are well-prepared in an academically rigorous setting with a heart grounded in Christ, like what a beautiful gift that is to Memphis. And so sometimes we hear all of the polarizing stories and the separation, and even in school choice discussions, it's this othering of, "how could you be for that or how could you be for this?" And it's like, "No, we want each kid to become more like Christ." And we do that best when we do that in community. And I feel like that's what you're living out. Now. Joi, can you talk a little bit about that experience of going to ECS? We've worked with ECS, a really fascinating school. How helpful was that office to you? Obviously you were successful, you went on to college, you're part of that 99.9% that Lionel talked about, but what was that experience like as a student? Joi: Honestly, it was really difficult. When I graduated, it was still in the early years of our alumni scholarship or support office, and so they were really still trying to understand how to get involved and be on the campus and really understand the difficulties we were experiencing as alumni going to these schools, because as Lionel stated, that New Hope is a predominantly black and brown school. And so when you leave this place and go to a predominantly white school, I mean, when I say culture shock, that's seriously what I was feeling as a seventh grader. We're already teenagers and crazy and feeling all kinds of ways. And so being in a completely new environment without my family really, we went through kindergarten through sixth grade together. And so leaving them and being placed in a completely new situation, it was really hard. It was really, really difficult. But the ASO office, they were there and they walked with me through all of those obstacles and difficulties and challenges that I faced, and they really encouraged me to just keep going because I was going to come out gold in the end. Even though it was some hard times, there was a lot of beauty in that as well. I tell a lot of people, the ECS definitely helped me academically. I mean, when it came to college, I was so ready. I didn't even blink to some of the work that they were throwing at me. But also spiritually. I mean, it really gave me that foundation of the Bible and knowing these verses and scriptures. Whenever I'm in these science classes or philosophy classes, and they really want to deter you from thinking that Jesus is the Savior and he is the creator, it really just gave me a foundation to know who I am, whose I am, I'm a daughter of the King, and it just really gave me a push to really get through everything. So I think I came out gold from doing all of that and trying to navigate it. Jon: Yeah, that joy through struggle is something that I think our current students have a hard time understanding. I mean, we want adversity. We don't want trauma. And so certainly going outside of your comfort zone to a new campus with support, that's adversity. We don't want it to bleed into trauma because I think through that adversity, we grow and become more of who we're created to be. And that's part of learning. I mean, that's the zone of proximal development. It's where you're at on your own versus what you can do with others through struggle, and that's where real joy is, and that's where transformation happens. So you would do some interesting things, Lionel, at your school with the forest and the farm. These aren't typical things that you think of in urban settings. Can you talk a little bit about what you're doing there and what the idea behind all that is? Lionel: Yeah, it was 2013, Mary Leslie Ramsey, who was the teacher that came up with the idea. We had recently been gifted the land from Habitat for Humanity, it's right across the street. They wanted to actually turn it into a subdivision, but found out it was on a floodplain, so couldn't do anything with it, so they gave it to us. She woke up one day with the head of school at the time and said, "Hey, the Lord has given me a vision. Do you see it? Do you see it?" And he kept saying, "I don't see a thing," because there was nothing there. And she said, "No, do you see this farm and this forest?" So she talked him into it, and obviously we didn't have a budget at the time to get it started. So we partnered with the Memphis Botanic Garden and they gave us all of the plantings that they were going to throw away. And it just really started with this small idea. Since Frayser is a fresh food desert, and the majority of our kids are either apartment dwellers or they don't necessarily go outside like they should, Mary Leslie just, she had the idea, "Okay, we've got to get our kids outside and we've got to expose them to something completely different than what they're used to." So that's when the farm and the forest was birthed. Currently, it is sitting on about five and a half acres. About one and a half of those acres, that's the actual farm. And it's more agricultural than it is animals. So our kids grow anything and everything from cabbage to strawberries to harvest their own honey. I mean, you name it, it is there. I'd like to think of it as the Garden of Eden because in the middle of Frayser, you wouldn't expect just this beautiful farm and forest that is there. We've got a full-time horticulturist who pours into that, and our teachers are able to go out there and do some applicable things with everything that is growing out there. With what's happening in the classroom, the forest piece is about four, four and a half acres, and we look at that as more of our play space. There are birdwatching observatories, there's about 1.7 miles of a walking trail that has been excavated there. I mean, just a beautiful space. And it's a way for our kids to really connect with our Lord. I mean, there's no better way to put your hands in the ground to plant something and just see how good God is by something coming up out of the ground. Jon: So you've got to tell me, how good are your kids at avoiding the instant gratification trap that gets really exposed in gardening. So they see something that is not even close to ripe, like that's it. I want to try it. Are they good at leaving it and letting it develop to its fullness of what the Lord wanted before they indulge? Or do they give in to that childlike instant gratification of the underdeveloped prefrontal cortex? Lionel: Yeah. Yeah, I think it's pretty developed. Jon: Okay. Lionel: Probably not at the beginning. And let me tell you why. So a part of Mary Leslie's strategy was also to give back to the Frayser community, so our kids understand the things that we plant, it's going towards a common good. So with this being a fresh food desert, every Friday, starting in late March all the way through, I'd say the end of October, we have what is called a pay what you can stand. And we invite the entire Frayser community to come in and grab as much produce as they'd like, and they can pay something or they can get it for free. So our kids know that, hey, we got to wait. We want that fruit to get ripe or those vegetables to be fully developed because it's going towards a good cause. Jon: That is so beautiful. The reason why I ask is last week I was at a school that's in a juvenile detention center down here in Texas, and they have violent youth offenders. They have quite a range of kids from age 13 to 18, and they have a garden. And in the English class, they were writing about weeds and the weeds they have in their own lives and then going out and weeding and tilling this garden. It was this beautiful lesson, but there was a very underdeveloped cucumber that one of the guys picked up and started munching for about 15 seconds. Until then, it's all out all over the ground because it was not ready. And the guy who's in charge of the garden says, "Yeah, they lose about 90% of the produce to kids not being able to delay that gratification to the point that it is ripe." And I think your point about they're doing this for someone else, that changes the calculus, that changes what it is. And now these kids are in juvenile detention through a series of tragic circumstances, bad decisions. Some of it may be related to not being able to delay gratification or not having the security of believing that something will be there the next day and not just taking what's available right now. But it was a fascinating lesson. So when you started talking about what your kids do, I was like, "Oh, I got to hear it." I had not thought about what a great lesson in delayed gratification gardening is. Because you take that too early and that thing that's going to be amazing in a week is inedible in the moment. So I love that. I love that. Joi, you're telling the story from a development fundraising perspective. Anything you want to add to what New Hope's doing that you think is particularly compelling? Joi: Yes. When I was a student at New Hope, we always craved for a middle school or a high school. We wanted to be at New Hope for as long as we possibly can. So for me to be here at New Hope, at the start of the transition of us actually bringing in a middle school, I mean, that's amazing to me. It feels like my sixth grade dreams are coming true right before my eyes. So I'm excited that I get to extend this type of opportunity to the current fifth graders who are here now. And then to the rest of the generations who are coming through, that they really get a chance to be involved and get this, it's like an incubator for Christ-Centered leadership and learning service and different activities that they get a longer chance to kind of experience that before they enter into high school where it really gets crazy. Middle school is just the beginning, but high school, I feel like we give them a chance to be prepared and cultivate their social emotional learning process needs that they have, so that when they are in those frightening or new situations, that they feel more prepared how to navigate these things. And so I think that's one of the best things that I'm excited about preparing or clearing out a new pathway for our students to really get time here with us here at New Hope. And then of course, it's our 30th anniversary. That's a huge deal. I don't know if we ever thought we would see this kind of day, but we're so blessed and thankful that we've made it. God has been with us the whole time. We've had a lot of obstacles, but we've come out on top every single time because his hand has been over us. And so I want to offer more partnerships and relationships to the community, especially right now. We have a really hectic education system going on, atmosphere in Memphis right now. So I really feel like this is a great time to amp up New Hope and tell more people about it because they are getting fearful and worried about what their child's education really will look like in the future. But we have been stable. We've been here for 30 years, and hopefully we can open our doors to more people. Jon: Yes. Love it. Love it. And the fact that you can describe middle school as a dream and not a nightmare, is a true testimony to the work of the spirit at New Hope. So love it. As a former middle school teacher and a middle school kid, I think I would have loved being at your farm and forest and in the culture you've built at New Hope. So that's a beautiful thing. We always end with a lightning round where I'll just ask a few questions and we just keep the answers to about a sentence if you can. I'm terrible at this, but if you can, that's better than me. So the first question is, what's the worst piece of advice you've ever received, as an educator or as a student, but just worst piece of advice you've ever gotten? Lionel: I guess I'll go first, Joi. Joi: Go ahead. Lionel: Honestly, I don't think I've ever gotten really bad advice. It may not have worked out because there's learning and failure. I just learned not to do that again, but I learned from it. So to answer your question, no bad advice. Jon: Well, one thing, Lionel, I would say that the piece I always give is people tell you to stay in your lane. And I feel like that's bad advice many times. And if New Hope would have stayed in its lane, you wouldn't have scholarships to send people off to school. You wouldn't exist. You wouldn't have a farm, you wouldn't have the wood. So I'm applying my bad advice that I received to New Hope as a counter example, and I'm grateful for educators that step up and speak out about, here's what we need, here's what we need to flourish, and here's what we need to do together. So I'll apply my bad advice to your good counter example. So thank you for that. Joi, what about you? Have you gotten any bad advice or are you as blessed as Lionel is to never have received bad advice? Joi: No, I think I have gotten bad advice before. Being in this new situation, raising money for an independent black school in Memphis, I think people have definitely told me that there are certain groups of people and populations I shouldn't ask money for support from or any type of activity from. But we're learning that our parents, our grandparents, the people in our community might be great people who can give and be a part of this whole mission that we have going on in New Hope. It doesn't have to be one specific person or they have to look a certain way. This is an opportunity for all. Jon: That's good. All right. Best advice you've either given or received? Joi: I will say the best advice that I think I've gotten actually come from Lionel. It was a couple of years ago, I was still in my previous job and antsy to get back home and to do work here at New Hope. And I talked to Lionel about it, "Like, why is it this not working out? I want to be here." And he told me to be still and wait on the Lord. And that's been the best advice because look where I am a couple of years later. I'm here and an opportunity to really lead in a big way, bigger than what I was trying to do earlier. So being still. Jon: Psalm 46:10, always good advice. All right. Lionel, what about you? Lionel: Yeah, you may have heard this one already, Jon. I think this advice came from my sister. About 10, 15 years ago, I had an opportunity, between two schools, to be the principal. One, was the highest performing school in the district, the other was the seventh worst performing school in the entire state of Tennessee. I was offered both jobs. Go out to the car, called my sister, I'm like, "Hey, I think I'm going to decline the worst school. I just want to go to the best school." And keep in mind, Jon, I had no experience at a failing school at all. Simple advice from her. She said, "Lionel, God has really blessed you in your career. Why don't you do the exact opposite of what you want to do and watch what God does through you?" Jon: That's amazing. Lionel: At that point, I accepted the job at the other place, and that's all she wrote. I mean, it was the best decision of my life. Jon: Yeah, love that. You have told me that. And it's always a good story to hear that again. Because I think so often I want my desires to always be aligned with Christ. And the more I am praying, the more I'm in the word, the more that is likely. But so often, my selfish desires get in the way of what He wants. And so love that. Okay. What do you see as the biggest challenge for New Hope specifically for the next 30 years? What would you say? And then we'll go back to what's your greatest hope? But we'll start with the challenge first. Lionel: Yeah. Prior to this year, it was the funding model. I mean, it's flipped on its head. 93% of our dollars came from donations. Past 30 years, we've never been in the red. Praise God, thankful for that. Now that ESA's vouchers, all of that is here, there is a path forward. So I think the challenge is how can we leverage our 30 years of experience and create more new hopes? New Hope, we serve 44 different zip codes in Memphis. In the north Memphis area is where we planted our flag, but South Memphis is the most impoverished area in the city. And my dream, my desire, my hope is that we can plant our flag in South Memphis and create a New Hope South Memphis, and then hopefully a New Hope East Memphis. So many children here, Jon, they need teaching, learning, and discipleship, and they need hope. And New Hope can certainly provide that through the gospel, but then also change that family's trajectory just through high quality academics and just building that foundation. So in short, to answer your question, the challenge is, how do we get more dollars? How do we leverage the dollars we have? How do we create these partnerships so that New Hope can grow well beyond Frayser, which is where we are now? Jon: Joi, anything you'd add to that challenge? Joi: He is the visionary leader of New Hope Christian Academy, so I stand behind him. That's our goal and vision. That's what we're doing. Jon: That's great. So then what's your greatest hope for New Hope or education in general, what's your greatest hope? Lionel: Oh, that's a loaded question, Jon. Jon: I know. We ask good ones for the lightning round and try to get you to give a parsimonious answer. Lionel: Oh. For Memphis specifically, and I think there's two parts to that. Memphis specifically, I'm hopeful that the education system will look more like the Kingdom, in particularly the private schools. Because it's not, Jon. I mean, again, New Hope and Collegiate, which is our sister school, we're the only ones that are high poverty, high concentration of black and brown children. Other schools are the complete opposite. And I always say, if you don't like diversity, you don't like heaven, you're not going to like heaven. And the thing is, I mean, I'm hopeful that in the independent school space that there will be room for growth so that it can look more like the Kingdom and that the leaders will be more Kingdom minded. As it relates to just education? We need more urban Christian education. I think that's the key. In the core of the city, we need high quality options for families because that's where the concentration of brokenness is, and in every major city in America. So I'm very hopeful, you know that the lens will look towards just again, high quality urban Christian education in cities across America. Jon: Oh, yes. Love that. Rebecca McLaughlin says, "Don't miss the fact that Christianity is the most diverse multicultural movement in the history of the world. And the church is becoming increasingly black and brown in 2025." So that's a great word and appreciate your heart behind that. Joi, anything you'd add to your hope for where things are headed? Joi: Yes. I think when people think of Memphis, their mind goes to our crime rate, our history, our music, and our food. And I think one thing about Memphis that most people miss is that this is a place with a lot of opportunity. And I'm grateful that the ESAs and EFS has made their way to the Shelby County area because crime is a big issue here. Safety is a big issue here. But I do know that that's directly related and linked to poverty. And I know that poverty can be changed with quality education. And so I think this is a great time for us to really capitalize on, now's the time. New Hope is the place for parents and community members to pour into and send people to, and maybe even replicate a school like that in their own city or their own state, that this kind of gospel and movement that we're trying to spread actually spreads everywhere. Jon: That's great. This resonates with what the Spreading Hope Network does. They're based out of Minneapolis. I'm sure they're aware of you and hopefully you're aware of them. Love the heart, love the work you're doing. Our team, they got to visit, it all came back. Bill Sterrett was enamored with the farm and the forest. Loved it. The team loved it. So anybody that gets a chance to get through Memphis and visit, I know they find a welcome team there that is just doing good work. And it's an encouragement and there's great joy in the work that we get to do with kids. So thank you for your time. Appreciate your work on our advisory board, Lionel. Joi, it's great to meet you virtually. Hopefully we'll meet you in person soon, and thanks for all you do. Joi: Sure. Thank you. Lionel: Thank you.

Marie Louise Nilsson 2

Martinson Möter

Play Episode Listen Later Jun 4, 2025 62:25

Välkommen till Martinson Möter en podcast från fadderbarns organisationen Compassion – där varje samtal vill öppna upp en ny värld av tröst och tro, heligt hopp, mat och mod!I dagens avsnitt får du möta Marie Louise Nilsson en inspiratör med både eld i hjärtat och skärpa i blicken och värme i rösten. Hon är prästen med över 25 års erfarenhet inom EFS. En ledare för ledare. En vägvisare för församlingsbultande hjärta som längtar efter mer av Jesus.Marie Louise brinner nämligen för att hela Sverige ska få höra om Jesu stora kärlek. Det är också därför hon gör det hon gör på Alpha Sverige, en plattform där frågorna får plats och sökarna hittar hem. Uppvuxen i lilla Sätaröd utanför Kristianstad, mellanlandad i Åres fjäll och nu med sitt hjärta planterat i Göteborg tillsammans med familjen hon älskar. Hon är chokladälskaren som aldrig säger nej till en latte i handen och förvandlar varje butik till en "boutique" med glimten i ögat. Och ja, hon har sommarjobbat på Vero Moda, dock nästan utan lön, men… med en helt ny garderob. Vill du höra mer om det får du lyssna på förra avsnittet. För nu går vi raskt framåt, livet, ledarskap och latte avhandlas i höga hastigheter!Vi reser med henne genom flytten till pandemins Göteborg 2020, blickar tillbaka mot Undersåkers snötyngda gator och rör oss mot det som är djupast sant: Relationer. Äkthet. Öppenhet. DVS det som är viktigt på riktigt. Så spänn fast dig. För vi vill inte bara ha ett samtal. Babbla på ytan. Det här är en inbjudan till mod. Det är en inbjudan att våga leva ärligt, leva för Kristus – och låta kärleken få sista ordet. Och vad händer egentligen med ett hjärta när man öppnar sitt liv – som Marie Louise gjort – för ett fadderbarn från Kenya?Välkommen in i snälla, men sanna samtal. Välkommen till Martinson Möter med Marie Louise Nilsson! Hosted on Acast. See acast.com/privacy for more information.

jesus christ compassion kenya acast sverige jesu unders nilsson kristus relationer marie louise dvs kristianstad efs uppvuxen vero moda

Avsnitt 241 - Från Vatikanen till vibe av väckelse

vibe reformation luther sveriges vilka statistiken efs teologi kyrka svenska kyrkan joel halldorf franciskus vatikanen

Play Episode Listen Later May 30, 2025 53:22

I dagens avsnitt rör vi oss från påvar till radikaliserade pojkar och frågande präster. Magnus gästas återigen av Joel Halldorf. Som professor i kyrkohistoria fungerar Joel via tidningar, tv och radio som hela Sveriges fortbildare i religiösa frågor. De senaste veckorna har han ledsagat oss genom Påve Franciskus begravning och konklaven fram till Påve Leo XIV via sin substack Vit Rök. Magnus och Joel tar sats i händelserna i Vatikanen för att styra vidare samtalet in mot det religiösa skeendet i vårt land, inte minst bland unga män. Statistiken ger en fingervisning om att vi kanske står på tröskeln till en stilla väckelse. Vad behöver vi som kyrka göra för att denna rörelse inte ska gå oss förbi? Vilka saker behöver vi vara uppmärksamma på och vaka över?

Avsnitt 240 - Att rymma eller rymmas?

Proactive - Interviews for investors

Play Episode Listen Later May 23, 2025 50:29

Judith Fagrell är präst i Skara domkyrkopastorat och skriver sedan många år om kyrkan i bland annat tidskriften Pilgrim, tidningen Dagen, Kyrkans tidning och SPT. Just nu aktuell med boken “Att söka rötter - ett teologiskt svar på Svenska kyrkans kris”. Idag fortsätter Judith samtalet med Magnus om rörelsen bland ungdomar som söker sig till kyrkan. Judith skriver: »Om vi inte vill ha en kyrka som lever i evig adolescens måste vi odla självkritik, och i det ingår att problematisera vår självbild. Vem inkluderas i det kyrkliga "viet"? Det exklusiva "viet" får till och med mig, som är präst, att ibland fundera på om jag tillhör – är det då så konstigt att våra unga scrollar vidare till något mer greppbart, inrutat, inbjudande?«

vem pilgrims eller att reformation luther idag dagen svenska efs spt teologi skara kyrka svenska kyrkan kyrkans rymma

Sona Nanotech clears Endotoxin testing, preps for first-in-human Gold Nanorod trial

Play Episode Listen Later May 21, 2025 5:25

Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio joined Steve Darling from Proactive to announce a critical advancement as the company prepares for its first-in-human clinical study. Sona has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods using the Limulus Amebocyte Lysate (LAL) method, a widely accepted industry standard for evaluating medical and pharmaceutical products. The testing was conducted at a GLP-accredited U.S. laboratory operated by a leading global provider of MedTech and pharmaceutical testing services. The results showed that all tested samples passed with endotoxin levels below detection limits, ensuring that Sona's nanorods meet stringent safety standards. In addition, Positive Product Controls confirmed the test's validity, with recovery values between 98% and 130%, indicating no assay interference—a further validation of the product's safety profile. The EFS, which is pending ethics committee approval, is expected to begin patient enrollment and first dosing early this summer. The study will utilize the same batch of gold nanorods that passed the endotoxin screening, reinforcing confidence in the material's clinical readiness. With its novel biocompatible nanotechnology platform, Sona is pioneering a new generation of targeted medical therapies. This latest development places the company a step closer to clinical validation and eventual commercialization of its proprietary nanomaterials. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTreatment #MedicalInnovation #HyperthermiaTherapy #GoldNanoparticles #Immunotherapy #TargetedTherapy #CancerResearch #Biotech #MedicalBreakthrough #GoldNanorods

gold trial testing proactive glp clears preps medtech sona nanotech efs endotoxin

Avsnitt 239 - Livslögner och sanningsbegrepp

reformation luther vilka efs teologi kyrka livsl svenska kyrkan

Play Episode Listen Later May 16, 2025 60:46

Det är dags för ett nytt teologiskt forum tillsammans med Johannelundteologerna Tomas Nygren och Stefan Lindholm. Vi fortsätter samtalet om ungdomar, radikalisering och sanningsbegreppet – vad är objektiv och subjektiv sanning när det kommer till den kristna läran och bekännelsen? Vilka livslögner har vår generation köpt och gjort till sanningar och hur avslöjar man dem? Hur skapar vi sammanhang med både rymlighet och tydlighet?

Internal communication as a vital enabler of colleague engagement with Dr. Sarah Pass

The Future of Internal Communication

Play Episode Listen Later May 14, 2025 37:14

Since the MacLeod report was first published in 2009, Engage for Success (EFS) has become a flourishing all-volunteer collective for those passionate about colleague engagement. A senior lecturer at Nottingham Business School, Dr. Sarah Pass is a practice-oriented academic who concentrates on employee experience and engagement. As a member of the Engage for Success (EFS) Advisory Board, she co-leads the EFS annual survey, which benchmarks the engagement levels of the UK working population. In this episode, Sarah and Jen discuss the findings of the latest EFS survey, explore the four enablers of engagement and dig into why colleague voice is so important when seeking to build motivation and goodwill at work. About Dr Sarah Pass Dr Sarah Pass is a practice-oriented academic who concentrates on employee experience and engagement. She is a member of the Engage for Success (EFS) Advisory Board and co-leads the EFS annual survey, which benchmarks the engagement levels of the UK working population. Sarah leads EFS projects focusing on different aspects and influences of engagement in practice and is also Chair of the EFS East Midlands Area Network. Sarah is a Fellow of the RSA, an Academic Associate of the CIPD, and a member of the Involvement and Participation Association (IPA) Working Insights Group. In 2023, Sarah was ranked by HR Magazine as an Influential Thinker in HR. Sarah currently works as a Senior Lecturer at Nottingham Business School (NTU). Find Sarah on LinkedIn: https://www.linkedin.com/in/sarahpass/ Sarah at Nottingham Business School: https://www.ntu.ac.uk/staff-profiles/business/sarah-pass Engage for Success: https://engageforsuccess.org/

success uk pass engagement engage fellow vital involvement senior lecturer colleagues rsa macleod enabler internal communication cipd hr magazine efs

Påskens vittne - Lange

EFS kyrkan i Ängelholm

Play Episode Listen Later May 11, 2025 38:36

När EFS 1861 tog ett beslut om att sända missionärer för tjänst bland "hednafolken" så var drivkraften förankrad i missionsbefallningen. Jesu egna sändningsord - gå ut i hela världen.... Lange var en av tre som 1866 landsteg i Massawa i nuvarande Eritrea.

lange jesu eritrea efs

Påskens vittne - Lange

Predikan från efs-kyrkan.tv

Play Episode Listen Later May 11, 2025 38:36

lange jesu eritrea efs

Avsnitt 238 - Många lärare, få andliga föräldrar

Taco Bout Fertility Tuesdays

Play Episode Listen Later May 9, 2025 45:43

Efter en ofrivillig paus är vi tillbaka och tar tag i vårens stora snackis! Helena Cashin, EFS kommunikationschef och Budbärarens chefredaktör är tillbaka och samtalar med Magnus om ungdomar som flockas till kyrkan och kyrkans ibland oförberedda eller ängsliga mottagande. Debatten pågår som bäst och har uppmärksammats långt utanför kyrkans egna forum. Samtalet är viktigt och här finns flera viktiga perspektiv att ta hänsyn till. Kanske framförallt att en föräldralös kyrka förmodligen alltid kommer förbli barnlös.

rare reformation luther efter debatten kanske samtalet m nga efs teologi kyrka svenska kyrkan andliga

AUA 2025 special: Dr. Neal Shore discusses phase 3 CREST study results

EAU Podcasts

Play Episode Listen Later May 3, 2025 12:11

At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC). Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

las vegas study shore bcg crest urology phase 3 bladder cancer efs nmibc

Frihetens konge | Daniel Sæbjørnsen | 21. april 2025

Passion Åsane

Play Episode Listen Later Apr 21, 2025 45:10

På mandag stilte Daniel spørsmålet: «Hva er roten til fangenskapet vi erfarer i våre liv – og finnes det håp for meg?». Vi så på følgende overskrifter: - Vårt fangenskap (Joh 8:34): Den dypeste roten til vårt fangenskap på ulike områder av livet, er hva Skriften kaller synd.- Våre fiender (Matt 4:1-11; Joh 8:44; Efs 4:26f; 1. Joh 2:15f): Gjennom Jesu fristelser og den kristne tradisjon, ser vi at synden primært angriper oss gjennom tre fiender: djevelen, kjødet og verden. Djevelen plager oss med løgner, som spiller på forvrengte lidenskaper i oss, som igjen finner veien inn i verden og kulturen rundt oss – sammen danner dette en ond og selvforsterkende sirkel. - Vår frelser (Hebr. 9:26; Kol. 2:15): Den kristne fortelling ender ikke i sorg, men i seier! Ved Jesu død og oppstandelse, så blir Han vår stedfortreder og seierherre! Kampen mot våre tre «sjels fiender» er virkelige, men den fantastiske sannheten er at den kristne kjemper fra frihet og ikke for frihet – siden Jesus har vunnet seier! Evangeliets frihet er det dypeste svaret til ethvert fangenskap i våre liv. Denne frihet erfarer vi ved: - Å ta imot evangeliet (høre)- Tro evangeliet- Trå ut i evangeliet Du er skapt til et liv i frihet og Jesus er vår seier!____Hovedtekst: Se prekenoppsummering.____1. Gå gjennom de ulike overskriftene: Les tekstene og snakk om hvordan de ulike områdene treffer våre liv. 2. Hvilke områder i ditt liv trenger du at Jesus «bryter lenken» som holder deg fast? 3. Avslutt med å be for hverandre inn i de områdene!

jesus christ denne hva hvilke kol tro joh hebr konge efs skriften frihetens djevelen

Where Did My Eggs Go? Unpacking the Myth of Empty Follicle Syndrome

Play Episode Listen Later Apr 2, 2025 13:22 Transcription Available

Send us a textYou've done the ultrasounds, the shots, the bloodwork — and then retrieval day comes, and... nothing. Zero eggs. What just happened?In this episode of Taco Bout Fertility Tuesday, Dr. Mark Amols dives into one of the most confusing and emotionally crushing outcomes in IVF: Empty Follicle Syndrome (EFS). But before you panic, know this — most cases aren't what they seem.We'll break down:The difference between true vs. false EFSWhy true EFS is rarer than a unicorn eating tacosHow trigger shot timing and hormone levels can lead to confusionWhat doctors actually mean when they say “empty follicle”Real strategies for preventing and managing this situationWhether you've heard the term before or are just trying to understand your IVF journey better, this episode will give you clarity, peace of mind, and as always — a side of science and salsa.Thanks for tuning in to another episode of 'Taco Bout Fertility Tuesday' with Dr. Mark Amols. If you found this episode insightful, please share it with friends and family who might benefit from our discussion. Remember, your feedback is invaluable to us – leave us a review on Apple Podcasts, Spotify, or your preferred listening platform. Stay connected with us for updates and fertility tips – follow us on Facebook. For more resources and information, visit our website at www.NewDirectionFertility.com. Have a question or a topic you'd like us to cover? We'd love to hear from you! Reach out to us at TBFT@NewDirectionFertility.com. Join us next Tuesday for more discussions on fertility, where we blend medical expertise with a touch of humor to make complex topics accessible and engaging. Until then, keep the conversation going and remember: understanding your fertility is a journey we're on together.

spotify real reach myth syndrome empty unpacking eggs fertility ivf infertility reproductive health reproductive endocrinology fertility treatment efs follicle fertility podcast

An Overview of AWS Cloud Storage Services | Benefits of AWS Cloud Storage

InfosecTrain

Play Episode Listen Later Mar 21, 2025 34:53

In this episode of the InfosecTrain podcast, we explore AWS Cloud Storage Services, their key features, and how businesses can leverage them for scalability, security, and cost efficiency.

benefits services best practices aws use cases glacier durability cloud storage ebs efs aws cloud cost optimization fsx

Avsnitt 237 - Lag & Evangelium

reformation luther martin luther evangelium annars skillnaden efs teologi kyrka svenska kyrkan

Play Episode Listen Later Mar 21, 2025 59:50

Det är återigen dags för teologisk verkstad och idag samtalar Tomas, Stefan och Magnus om begreppsparet lag och evangelium. Martin Luther behandlade frågan ingående och det är ett av hans viktiga bidrag. Luther menade: »Skillnaden mellan lag och evangelium är den kristna trons främsta kännetecken. Alla som räknar sig som kristna bör känna till och kunna redogöra för denna skillnad. Annars kommer man blanda ihop dem och inte att känna till och bevara någondera, varken det ena eller det andra.« Hur kan vi förstå och kommunicera lag och evangelium i vår tid och vilken tröst kan det skänka eller vilka potentiella problem kan det skapa?

Avsnitt 236 - Kyrkan i Babylon

Play Episode Listen Later Mar 14, 2025 48:46

Pastor Simon Holst från Bet:L i Skövde gästar dagens avsnitt och med utgångspunkt i hans senaste text i Tidningen Dagen samtalar han med Magnus om missiologi för vår tid. En negativ värld behöver inte vara något negativt för kyrkan, utan kan bli tvärtom bli till en guldålder för de kyrkor som vågar stå för och predika ett frimodigt evangelium, lyder Simons spaning. Utifrån tre tids epoker som i texten kallas för positiv värld, neutral värld och negativ värld diskuterar Magnus och Simon hur kyrkan kan finna ett lämpligt och gångbart föredöme i profeten Daniel som verkade i Babylon.

babylon reformation luther simons utifr kyrkan efs teologi kyrka svenska kyrkan

Avsnitt 235 - Ärligt och härligt om skam, beroende och frihet

Play Episode Listen Later Mar 7, 2025 45:10

Magnus gör ett kärt återseende med Aminah Fallgren och lyssnar till hennes fantastiska berättelse! För drygt 20 år sedan dök Aminah upp i kyrkan där Magnus var pastor. Då som en drogmissbrukare sedan 12-års ålder som hade alla sina ägodelar i en väska. Idag har hon varit drogfri i 20 år, blivit beroendeterapeut, är VD och driver egen framgångsrik behandlingsverksamhet som hjälpt åtskilliga. Förutom Aminahs egen inspirerande berättelse om befrielse, tillfrisknande och nya möjligheter, så samtalar Magnus och Aminah om den kamp som alla människor utkämpar med skam, sökande efter bekräftelse, kärlek och frihet. Missa inte ett ärligt och härligt samtal som berör!

reformation luther idag missa vd skam frihet beroende aminah efs teologi kyrka svenska kyrkan

Avsnitt 234 - Du blir vad du äter - om nattvarden

factors emission generic efs

Play Episode Listen Later Feb 28, 2025 58:24

Det är åter dags för ett teologiskt forum med Johannelunds teologerna Tomas Nygren och Stefan Lindholm. I dagens avsnitt samtalas det om nattvarden. Det något högst påtagligt och verkligt som sker i nattvarden och inte bara symboliskt. Därför kallas sakramenten nådemedel – kanaler genom vilka Gud sänker sin nåd och åstadkommer vad han lovar. Kan man därför säga att nattvarden skapar den verklighet den gestaltar? Häng med i dagens samtal!

reformation luther blir gud efs teologi kyrka svenska kyrkan johannelunds

SoS#39: Are Generic Emission Factors Over?

State of Sustainability

Play Episode Listen Later Feb 27, 2025 33:57

Emission Factors (EFs), as we know them, are over. Bold statement? Maybe. True? Absolutely (in our opinion). In this episode, we break down why traditional emission factors are rapidly being replaced by Product Carbon Footprints (PCFs) and what this shift means for businesses.The limitations of traditional emission factorsWhy PCFs provide more accurate, supplier-specific dataWhere businesses need to focus their efforts as PCFs scale upKey considerations when transitioning from EFs to PCFs

Avsnitt 233 - G som i gudsbilder och gemenskaper

reformation luther dagens efs teologi kyrka svenska kyrkan

Play Episode Listen Later Feb 21, 2025 53:15

EFS kommunikationschef och Budbärarens chefredaktör, Helena Cashin, är tillbaka i podden för en ny runda spaningar tillsammans med Magnus. Dagens avsnitt är fullspäckat och matnyttigt, det spänner över frågorna om kyrkan och gemenskapen såväl som kyrkan och gudsbilder. Har vi skapat en gudsbild som är en projektion av oss själva och våra egna trauman eller önskningar? Vi är hyfsat bra på gudstjänst men vad händer med gemenskapen? Vad innebär det att forma kristna gemenskaper?

Avsnitt 232 - Hela vägen går han med mig

Play Episode Listen Later Feb 14, 2025 35:27

Podden gästas idag av Samuel Björling, musikinspiratör vid EFS Sverigeavdelning. Magnus och Samuel samtalar om kyrkans sång och musik, lovsång och förkunnande sång framförd av solist, nytt såväl som gammalt. Samuel är ansvarig för senaste musiksläppet på Cantio: en EP med namnet ”Hela vägen går han med mig” och konferensen med samma namn. Magnus och Samuel berättar också om de ”helkyrkliga inspirationsdagar” de erbjuder församlingar samt den helkyrkliga mässan som fler och fler visar intresse av.

reformation luther hela podden geng efs teologi kyrka svenska kyrkan

Avsnitt 231 - Inne- & utelistan 2025

reformation luther inne gregorio josefin svenska dagbladet efs teologi kyrka svenska kyrkan

Play Episode Listen Later Feb 7, 2025 38:47

Litteraturvetaren och litteraturredaktören på Svenska Dagbladet, Josefin de Gregorio, gästar podden igen för att göra om sin bejublade medverkan förra året. Josefin presenterar en »inne- & utelista« för 2025 utifrån kristenheten. Magnus och Josefin samtalar utifrån listan om många spännande ämnen som kontemplation, framgångsteologi, kristna som bråkar på internet, avgudadyrkan, väckelse och barnens närvaro i kyrkan. Här finns mycket spännande!

Tror du detta?

EFS kyrkan i Ängelholm

Play Episode Listen Later Feb 2, 2025 25:15

Ängelholm Pingstförsamlings pastor Sven Wiborn predikar över Joh 11:21-27 i EFS-kyrkan som avslutning på den ekumeniska böneveckan. Samverkar i gudstjänsten gör även Ängelholms församling, Rönnekyrkan och ELM Ängelholm.

detta tror elm joh efs pingstf

Tror du detta?

Predikan från efs-kyrkan.tv

Play Episode Listen Later Feb 2, 2025 25:15

detta tror elm joh efs pingstf

En déplacement dans les Vosges, Frédéric Pacoud, le président de l'EFS, appelle aux dons de plasma

Les invités France Bleu Sud Lorraine

Play Episode Listen Later Jan 31, 2025 5:54

durée : 00:05:54 - L'invité de la rédaction de "ici Sud Lorraine" - La collecte du plasma est la priorité de l'établissement français du sang (EFS) en 2025. Pour mobiliser les Français, Fréderic Pacoud, le président de l'EFS est en visite ce vendredi à Remiremont (Vosges), où il rencontre donneurs et élus locaux. Il a pris le temps de répondre à nos questions.

dans dans les aux placement plasma dons le pr appelle vosges efs

Avsnitt 230 - Tro och dop hör ihop

Play Episode Listen Later Jan 31, 2025 60:38

Det är dags för en ny omgång teologiprat med Johannelund teologerna Tomas Nygren och Stefan Lindholm. I dagens avsnitt avhandlas dopet som sakrament och vad det förmedlar från Gud och hur det förhåller sig till tron. Räcker dopet eller vilken roll spelar tron? Ska man bygga sitt dop på sin tro eller sin tro på sitt dop - vad Gud har skänkt och gjort i dopet oberoende av med min egen medverkan? Hur kan vi berikas från olika teologiska perspektiv - kan lutheraner lära sig något av baptister och tvärtom?

reformation luther ska ihop gud efs teologi kyrka svenska kyrkan

Avsnitt 229 - Riv bort taket

reformation luther idag bort efs taket teologi kyrka svenska kyrkan equmeniakyrkan

Play Episode Listen Later Jan 24, 2025 53:57

Ida-Maria Brengesjö är evangelist och församlings-utvecklare inom Equmeniakyrkan och aktuell med boken »När taket måste brytas upp«. Idag gästar hon podden och samtalar med Magnus om frågor kring kyrkans rymlighet och öppenhet – leder det till flummighet eller går det att kombinera tydlighet med generös rymlighet?

Avsnitt 228 - Dopglöd

Play Episode Listen Later Jan 17, 2025 35:47

I söndags var kyrkoårets tema »Jesu dop« och det följer vi upp med att tala om just dopet. Martin Luther skriver att ”det är uppenbart att dopet inge handlar om något som vi människor gör, utan om en skatt som Gud skänker och som vi tar emot genom att tro.« Magnus samtalar med Simon Sjögren från Verbum om deras nya satsningar »Dopkraft« och »Dopglöd« för strategiskt arbete med att stärka dopets innehåll, plats och roll i församlingslivet.

reformation luther martin luther jesu gud efs teologi kyrka svenska kyrkan verbum simon sj

Avsnitt 227 - Kyrkan, Vineyard och 12-stegsrörelsen

reformation vineyard sverige luther idag torbj celebrate recovery kyrkan efs teologi kyrka svenska kyrkan

Play Episode Listen Later Jan 10, 2025 45:49

Torbjörn Freij är sedan länge en profil inom kristenheten i Sverige. Baptistpastor, ledarskribent på Tidningen Dagen, författare till flera böcker och ledargestalt inom såväl ekumenisk förnyelse som Vineyard. Idag är Torbjörn intensivt engagerad i Celebrate Recovery, en kristen variant på 12-stegsprogram men inte bara för traditionella substansmissbrukare utan även för oss alla »normalstörda och vanliga människor«. Här skapas en plats och ett program där man även får bearbeta störningar, söndrighet, sår, ovanor och laster. Vad kan den traditionella kyrkan lära sig av Vineyard och 12-stegsrörelsen?

531- How to Manage Executive Function and Working Memory Challenges: A Guide for Adults with ADHD

ADHD Experts Podcast

Play Episode Listen Later Dec 17, 2024 60:37

Executive functions are the skills that allow us to plan for and meet goals, manage time effectively, remember what we've heard and read, and exercise self-control. Peg Dawson, Ed.D., shares strategies you can use to improve your EFs and cement habits. Executive Functioning in Adults: More Resources Self-Test: Do You Have a Working Memory Deficit? Read: 7 Executive Function Deficits Tied to ADHD Read: How Adults with ADHD Think eBook: The Adult's Guide to Stronger Executive Functions Access the video and slides for podcast episode #531 here: https://www.additudemag.com/webinar/executive-functioning-adults-adhd-strategies/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

guide challenges habits executives adhd manage executive functions executive functioning working memory efs executive dysfunction additude adults with adhd

MAGNUS PERSSON

Brittas vardagsrum

Play Episode Listen Later Nov 1, 2024 54:33

Själens slagfältEtt personligt och närgånget samtal med Magnus Persson, präst och inspiratör i EFS. Om sjukdom, kamp och ovisshet. Vi delar personliga erfarenheter och jag fångar upp Magnus starka beskrivning om själens slagfält när en plötslig sjukdom gör att styrka blir svaghet. I samarbete med Magnus podcast: Re:formera.

sj efs magnus persson

Radio Show 560 Empowering employees through wellbeing at Lipsy London

success engage wellbeing radio show highlighting breweries communications manager empowering employees efs

Play Episode Listen Later Oct 3, 2024 34:19

Guest: Anais Nebel: Group Culture and Communications Manager, Lipsy Anaïs is a culture leader and brand strategy expert, passionate about people empowerment. She leads culture and communications for Lipsy, a fashion and beauty group made up of 7 brands including Victoria's Secret UK and Gap UK. Anaïs is known for creating out-of-the box engagement campaigns that create vibrant connections and bring the soul of a company to life. This special episode was recorded following Jo and Anais interview on stage at the 2024 Employee Engagement Summit at the Brewery in London and is hosted by Jo Moffatt, Engage for Success Advisory Board member and regular EFS radio show host. Engage for Success are media partners for Engage Business Media's industry-leading events, including the Future of Work Conference and the Employee Engagement Summit. • The key drivers that led to Lipsy London taking action to add self-empowerment to their wellbeing strategy • Why Lipsy London decided to run a photoshoot initiative • Any challenges in getting employee buy-in • Highlighting the key results that have been seen following the photoshoot • What's next for self-empowerment at Lipsy? • The achievements and impact that create the most pride Join us as we discuss how Lipsy London's recent wellbeing initiative empowered employees through self-confidence. Host: Jo Moffatt

Show no. 560 Empowering employees through wellbeing at Lipsy London

success engage wellbeing breweries communications manager empowering employees efs

Play Episode Listen Later Sep 30, 2024 35:00

Smith Transport August 2024 Newscast

Play Episode Listen Later Aug 21, 2024 18:45

Smith Anniversaries, a retirement announcement, EFS updates, customer service news, Brake Safety Week, Clean Inspection Roll Call, Shout Outs with Julie, and Doug's Dad Joke of the Week! #smithtransportdotcom #peterbilt #cld #truckers

shoutouts transport dad jokes newscast efs brake safety week

Smith Transport July 2024 Newscast

safety operations recruiting customer service maintenance transport dad jokes bedford newscast dougs efs

Play Episode Listen Later Jul 11, 2024 21:00

Smith Transport brings you the latest July monthly newscast brings news from Customer Service with scorecards and on-time pick-up and deliveries, Safety has clean inspections and safety tips on rider program and pet policy. Joe from Operations talks about EFS cards, service, and the increase in freight. Maintenance talks about ways to save your truck batteries. Recruiting has new openings on our dedicated fleet in Bedford, PA. Jenn is here with Smith-A-Versaries, and of course we have Dougs 'Dad Joke of the Week' #safety #service #peterbilt #award #cdl #trucker #trucking #smithtransportdotcom

Radio Show #547 Harnessing Employee-Driven Engagement

success employees engagement driven engage harnessing radio show breweries fireside chat erg deliveroo efs

Play Episode Listen Later Jul 3, 2024 20:12

Guest: Christina Lewis: Gender Equity ERG Lead/Head of Global Rider Experience, Deliveroo Christina leads Deliveroo's Gender Equity Employee Resource Group alongside her role as Head Of Global Rider Experience. In her ERG role, Christina spearheaded the first woman-focused mentoring scheme, as well as introducing accelerate, Deliveroo's programme for high potential women. Christina leads a team of 10 ERG members, focusing on gender equity at Deliveroo. This special episode was recorded live on stage at the 2024 Employee Engagement Summit at the Brewery in London. It takes the form of a ‘Fireside Chat' hosted by Jo Moffatt, Engage for Success Advisory Board member and regular EFS radio show host. Engage for Success are media partners for Engage Business Media's industry-leading events, including the Future of Work Conference and the Employee Engagement Summit. Christina Lewis, Deliveroo's Gender Equity ERG lead and award-winning ‘WiHTL Woman To Watch 2024' explains how ERG groups can boost company culture & employee engagement, drive impact for underrepresented groups, give grassroot insight, as well as the pitfalls to avoid. Join us as we discuss how volunteer led employee resource groups help support company culture and employee proposition. Host: Jo Moffatt

Radio Show #547: Harnessing Employee-Driven Engagement

success employees engagement driven engage harnessing radio show breweries fireside chat erg deliveroo efs

Play Episode Listen Later Jul 1, 2024 21:00

Smith Transport June Newscast

Play Episode Listen Later Jun 25, 2024 17:09

Smith Transport, HQ in Roaring Spring, PA is an asset truckload dry van carrier that travels east of I35 with 800 drivers. If you're looking for a truckload carrier that offers safety and service, call us at 888 GO SMITH. This monthly newscast is the voice-only version of our YouTube, Facebook newscast. We offer you monthly segments like Shout Outs, news from the shop, custom service, operations, and safety. This month there are updates on EFS cards, Smith Anniversaries, July CVSA details, Federal Inspections on your truck, Clean Inspection list, and an alternative to the Vector App, and more!

shoutouts transport hq newscast efs i35

Immunotherapy at ASCO24: NADINA and Other Key Studies

ASCO Daily News

Play Episode Listen Later Jun 19, 2024 34:51

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers. TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. You will find our full disclosures in the transcript of this episode. Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma. By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel. So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact. In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery. Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants. It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice. Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive. So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients. In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease. Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort. Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease. In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option. Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance. Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years? Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option. In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago. In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go? Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies. LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms. So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be. I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing. You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942. Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much. Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Diwakar Davar: Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

university ai spring 3d asian pittsburgh os cd studies fda congratulations pfizer keynote patel werewolf relation franklin delano roosevelt pd bayer immune pcr abstract oncology merck 2b endeavor cps 3b janssen new england journal novartis dor melanoma alc royalties lag accommodations hsv cancer care immunotherapy tps gsk asco 4a lm genentech 3c ldr orr abbvie bristol myers squibb stipe takeda nct igg regeneron adcc egfr gilead sciences adverse events md anderson rfs nektar pdl onc efs adcs prognostic cancer immunotherapy braf esmo neoadjuvant plenary session eisai immuno oncology asco annual meeting treg pyxis nccn nadina rubius servier michael wong ctla rp1 incyte emd serono ezra cohen lgr alnylam genmab tregs mcla moderna therapeutics gm csf swog ignyte ctla4 rp2 recist tesaro jason luke transcript dr igg1 array biopharma synlogic

Fuel Card Changes for Smith Transport